SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine prospectively in all patients with SCLC in second
line therapy that progression-free survival with the expected reintroduction of platinum /
etoposide is greater progression-free survival in the standard arm (topotecan ) in patients
who have relapsed at least three months after initial chemotherapy with platinum-etoposide